Your browser is no longer supported. Please, upgrade your browser.
VTVT vTv Therapeutics Inc. daily Stock Chart
vTv Therapeutics Inc.
Index- P/E- EPS (ttm)-0.47 Insider Own0.10% Shs Outstand43.46M Perf Week-13.07%
Market Cap188.31M Forward P/E- EPS next Y-0.59 Insider Trans- Shs Float9.80M Perf Month11.82%
Income-16.80M PEG- EPS next Q-0.10 Inst Own5.30% Short Float19.37% Perf Quarter15.49%
Sales1.90M P/S99.11 EPS this Y14.90% Inst Trans1.10% Short Ratio2.84 Perf Half Y20.59%
Book/sh-1.42 P/B- EPS next Y-40.50% ROA-192.30% Target Price- Perf Year90.70%
Cash/sh0.01 P/C470.78 EPS next 5Y- ROE32.20% 52W Range1.23 - 4.23 Perf YTD44.71%
Dividend- P/FCF- EPS past 5Y11.70% ROI49.00% 52W High-41.84% Beta-1.75
Dividend %- Quick Ratio0.30 Sales past 5Y12.30% Gross Margin- 52W Low100.00% ATR0.25
Employees26 Current Ratio0.30 Sales Q/Q-99.10% Oper. Margin- RSI (14)47.29 Volatility10.03% 10.41%
OptionableNo Debt/Eq- EPS Q/Q57.80% Profit Margin- Rel Volume0.33 Prev Close2.49
ShortableYes LT Debt/Eq- Earnings- Payout- Avg Volume668.51K Price2.46
Recom2.00 SMA200.45% SMA50-4.07% SMA20011.62% Volume226,416 Change-1.20%
May-30-19Initiated H.C. Wainwright Buy
Apr-10-18Downgrade Stifel Buy → Hold $12 → $1
Mar-08-18Initiated ROTH Capital Buy $17
Feb-08-18Initiated Northland Capital Outperform $28
Sep-26-16Initiated H.C. Wainwright Buy $13
Sep-04-15Initiated Canaccord Genuity Buy $15
Aug-24-15Initiated Stifel Buy $17
Aug-24-15Initiated Piper Jaffray Overweight $24
Aug-03-20 04:30PM  
Jul-27-20 07:30AM  
Jun-13-20 11:00AM  
Jun-04-20 07:08PM  
May-28-20 11:15AM  
May-27-20 07:30AM  
May-22-20 04:30PM  
May-12-20 10:38AM  
May-07-20 04:30PM  
Mar-12-20 11:30AM  
Mar-02-20 08:10AM  
Feb-25-20 05:00AM  
Feb-24-20 11:24AM  
Feb-20-20 06:58PM  
Feb-10-20 07:00AM  
Feb-07-20 04:05PM  
Jan-31-20 11:52AM  
Jan-10-20 12:32PM  
Jan-03-20 06:00AM  
Dec-19-19 05:45AM  
Dec-02-19 07:30AM  
Nov-15-19 03:04PM  
Nov-05-19 07:30AM  
Oct-30-19 06:55PM  
Oct-25-19 02:03PM  
Oct-03-19 07:30AM  
Sep-20-19 03:28PM  
Sep-18-19 07:30AM  
Sep-17-19 04:35PM  
Sep-13-19 01:32PM  
Sep-11-19 07:30AM  
Sep-06-19 04:06PM  
Sep-04-19 07:30AM  
Aug-09-19 04:09PM  
Aug-06-19 04:05PM  
Jul-31-19 04:30PM  
Jul-15-19 04:59PM  
Jun-28-19 01:03PM  
Jun-27-19 04:30PM  
Jun-06-19 08:00AM  
May-29-19 12:00PM  
May-17-19 05:47PM  
May-01-19 06:58PM  
Apr-04-19 10:49AM  
Apr-03-19 07:57AM  
Apr-02-19 07:30AM  
Mar-28-19 04:30PM  
Mar-19-19 12:56PM  
Mar-18-19 09:00AM  
Feb-27-19 08:30AM  
Jan-25-19 12:05AM  
Jan-16-19 02:00PM  
Jan-02-19 03:03PM  
Dec-31-18 10:50AM  
Dec-28-18 09:20AM  
Dec-03-18 07:30AM  
Nov-19-18 04:00PM  
Nov-08-18 08:45PM  
Oct-31-18 10:32AM  
Oct-29-18 06:30PM  
Oct-24-18 09:00AM  
Oct-17-18 12:27PM  
Oct-16-18 04:30PM  
Oct-15-18 08:10AM  
Oct-11-18 08:34AM  
Oct-10-18 10:30AM  
Oct-04-18 10:30AM  
Oct-03-18 08:00AM  
Aug-30-18 04:30PM  
Aug-22-18 02:56PM  
Aug-03-18 09:25AM  
Jul-30-18 07:20AM  
Jul-02-18 07:25AM  
Jun-22-18 09:00AM  
Jun-12-18 04:30PM  
Jun-08-18 07:30AM  
Jun-01-18 08:46AM  
May-31-18 07:33AM  
May-30-18 07:25AM  
May-15-18 04:52PM  
May-11-18 08:20AM  
May-09-18 04:30PM  
Apr-30-18 06:00AM  
vTv Therapeutics Inc., a clinical-stage biopharmaceutical company, discovers and develops orally administered small molecule drug candidates to fill unmet medical needs. The company is developing Azeliragon, an orally administered, small molecule antagonist targeting the receptor for advanced glycation end products, which is in Phase II clinical trials for the treatment of mild Alzheimer's disease. It is also developing TTP399, an orally administered, liver-selective glucokinase activator that has completed Phase II clinical trials to treat type 2 diabetes, as well as is in Phase II/III clinical trials for treating type 1 diabetes; and TTP273, an orally administered, non-peptidic agonist that targets the glucagon-like peptide-1 receptor, which has completed Phase II clinical trials for the treatment of type 2 diabetes. In addition, the company is developing HPP737, HPP971, and HPP3033 for the treatment of chronic disease. It has a license agreement with Reneo Pharmaceuticals, Inc. to develop and commercialize peroxisome proliferation activated receptor delta agonist program, including the compound HPP593. vTv Therapeutics Inc. also has license and research agreements with Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.; Newsoara Biopharma Co., Ltd.; JDRF International; Novo Nordisk A/S; and Columbia University. The company was founded in 2015 and is headquartered in High Point, North Carolina. vTv Therapeutics Inc. is a subsidiary of MacAndrews & Forbes Incorporated.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
KOZLOV HERSHDirectorMay 15Buy3.0010,00030,00015,000May 18 04:28 PM
PERELMAN RONALD O10% OwnerMay 12Buy1.60625,0001,000,00034,731,212May 12 04:32 PM
KINDLER JEFFREY BDirectorMar 10Option Exercise0.0011,667035,000Mar 11 04:12 PM
PERELMAN RONALD O10% OwnerFeb 25Buy1.601,250,0002,000,00034,106,212Feb 25 04:30 PM
PERELMAN RONALD O10% OwnerJan 28Buy1.601,250,0002,000,00032,856,212Jan 28 04:31 PM
PERELMAN RONALD O10% OwnerJan 07Buy1.601,250,0002,000,00031,606,212Jan 07 04:16 PM
PERELMAN RONALD O10% OwnerDec 18Buy1.461,369,8632,000,00030,356,212Dec 18 04:15 PM
PERELMAN RONALD O10% OwnerNov 26Buy1.461,369,8632,000,00028,986,349Nov 26 04:15 PM
PERELMAN RONALD O10% OwnerNov 12Buy1.461,369,8632,000,00027,616,486Nov 12 04:26 PM
PERELMAN RONALD O10% OwnerOct 24Buy1.461,369,8632,000,00026,246,623Oct 24 07:11 PM
PERELMAN RONALD O10% OwnerSep 27Buy1.461,369,8632,000,00024,876,760Sep 27 04:31 PM
PERELMAN RONALD O10% OwnerSep 18Buy1.65606,0611,000,00123,506,897Sep 18 04:40 PM
KOZLOV HERSHDirectorSep 13Buy1.655,0008,2505,000Sep 17 04:30 PM
PERELMAN RONALD O10% OwnerSep 11Buy1.65606,0611,000,00122,900,836Sep 11 04:42 PM
PERELMAN RONALD O10% OwnerSep 04Buy1.65606,0611,000,00122,294,775Sep 04 06:24 PM
PERELMAN RONALD O10% OwnerAug 22Buy1.3850,00069,00021,688,714Aug 22 06:37 PM
PERELMAN RONALD O10% OwnerAug 19Buy1.31150,000195,90021,638,714Aug 19 07:38 PM
SGMS Scientific Games Corporation daily Stock Chart
Scientific Games Corporation
Index- P/E- EPS (ttm)-4.14 Insider Own1.30% Shs Outstand95.00M Perf Week3.99%
Market Cap1.90B Forward P/E47.82 EPS next Y0.40 Insider Trans0.39% Shs Float56.01M Perf Month19.02%
Income-391.00M PEG- EPS next Q-0.78 Inst Own61.20% Short Float16.16% Perf Quarter73.45%
Sales2.98B P/S0.64 EPS this Y63.90% Inst Trans0.72% Short Ratio5.19 Perf Half Y-30.88%
Book/sh-27.29 P/B- EPS next Y108.80% ROA-5.00% Target Price16.78 Perf Year-4.13%
Cash/sh8.03 P/C2.40 EPS next 5Y- ROE16.50% 52W Range3.76 - 31.63 Perf YTD-28.04%
Dividend- P/FCF8.99 EPS past 5Y12.80% ROI6.90% 52W High-39.08% Beta2.55
Dividend %- Quick Ratio1.60 Sales past 5Y13.70% Gross Margin59.50% 52W Low412.50% ATR1.10
Employees9800 Current Ratio1.80 Sales Q/Q-36.20% Oper. Margin5.80% RSI (14)59.95 Volatility4.99% 6.88%
OptionableYes Debt/Eq- EPS Q/Q-158.10% Profit Margin-13.10% Rel Volume0.48 Prev Close18.77
ShortableYes LT Debt/Eq- EarningsJul 23 AMC Payout- Avg Volume1.74M Price19.27
Recom2.60 SMA2014.25% SMA5016.48% SMA200-0.27% Volume836,435 Change2.66%
May-21-20Resumed Credit Suisse Underperform $22 → $8
Jan-08-20Upgrade Stifel Hold → Buy $30 → $37
Nov-11-19Downgrade Susquehanna Positive → Neutral
May-08-19Reiterated Telsey Advisory Group Outperform $36 → $31
Mar-20-19Resumed Credit Suisse Underperform $21
Dec-07-18Initiated Susquehanna Positive $25
Nov-16-18Downgrade Jefferies Buy → Hold
Aug-08-18Reiterated Stifel Hold $46 → $44
Aug-03-18Reiterated Stifel Hold $57 → $46
May-24-18Reiterated Telsey Advisory Group Outperform $59 → $70
May-07-18Reiterated Telsey Advisory Group Outperform $54 → $59
Apr-04-18Reiterated Telsey Advisory Group Outperform $52 → $54
Mar-14-18Initiated Telsey Advisory Group Outperform $52
Feb-20-18Initiated Jefferies Buy $57
Sep-18-17Reiterated Stifel Hold $35 → $40
Jul-25-17Reiterated Stifel Hold $24 → $35
Apr-28-17Reiterated Telsey Advisory Group Market Perform $20 → $24
Mar-03-17Reiterated Telsey Advisory Group Market Perform $13 → $20
Jan-26-17Upgrade BofA/Merrill Underperform → Buy
Dec-16-16Downgrade Macquarie Outperform → Neutral
Jul-24-20 03:22PM  
Jul-23-20 05:35PM  
Jul-16-20 07:02PM  
Jul-15-20 05:00PM  
Jul-01-20 04:10PM  
Jun-30-20 09:05AM  
Jun-29-20 04:10PM  
Jun-18-20 01:21PM  
Jun-17-20 05:39PM  
Jun-16-20 09:45PM  
Jun-10-20 11:30AM  
Jun-09-20 11:06AM  
May-29-20 04:10PM  
May-27-20 09:05AM  
May-26-20 02:22PM  
May-22-20 11:37AM  
May-21-20 05:05PM  
May-18-20 04:10PM  
May-13-20 09:05AM  
May-12-20 09:44AM  
May-11-20 06:15PM  
May-08-20 04:51PM  
Apr-29-20 04:05PM  
Apr-28-20 12:33PM  
Apr-27-20 03:11PM  
Apr-23-20 09:05AM  
Apr-21-20 05:56PM  
Apr-20-20 06:08PM  
Apr-14-20 04:16PM  
Apr-13-20 09:05AM  
Apr-07-20 04:10PM  
Apr-02-20 08:33AM  
Apr-01-20 09:00AM  
Mar-31-20 05:26PM  
Mar-30-20 05:21PM  
Mar-28-20 08:52PM  
Mar-27-20 03:19PM  
Mar-26-20 05:02PM  
Mar-19-20 11:30AM  
Mar-16-20 11:13AM  
Mar-09-20 04:05PM  
Feb-27-20 06:10AM  
Feb-26-20 04:10PM  
Feb-25-20 12:44PM  
Feb-24-20 08:00AM  
Feb-20-20 11:50AM  
Feb-19-20 08:30PM  
Feb-18-20 04:01PM  
Feb-17-20 08:09PM  
Feb-14-20 01:05AM  
Feb-11-20 04:15PM  
Feb-07-20 11:30AM  
Feb-05-20 09:10AM  
Feb-04-20 08:11AM  
Jan-30-20 12:30PM  
Jan-29-20 01:10AM  
Jan-23-20 09:10AM  
Jan-21-20 09:00AM  
Jan-16-20 09:41AM  
Jan-15-20 09:10AM  
Jan-13-20 10:02AM  
Jan-10-20 11:50AM  
Jan-09-20 09:26AM  
Dec-19-19 09:29AM  
Dec-18-19 06:00AM  
Dec-16-19 06:00AM  
Dec-11-19 08:27AM  
Dec-10-19 04:10PM  
Dec-07-19 11:31AM  
Dec-05-19 04:10PM  
Dec-04-19 05:55PM  
Nov-26-19 04:10PM  
Nov-25-19 06:03AM  
Nov-19-19 09:46AM  
Nov-12-19 07:09PM  
Nov-11-19 03:27PM  
Scientific Games Corporation develops technology-based products and services, and related content for the gaming, lottery, social and digital gaming industries in the United States and internationally. The company's Gaming segment sells new and used gaming machines, electronic table systems, video lottery terminals, conversion game kits, and spare parts; slot, casino, and table-management systems; table products, including shufflers; and perpetual licenses to proprietary table games. It also leases gaming machines; provides gaming operations and licensing arrangements; and installs and supports casino management systems, such as ongoing hardware and software maintenance and upgrade services of customer casino management systems. The company's Lottery segment designs, prints, and sells instant lottery products; designs and manufactures instant games tickets; offers instant products planning, monitoring, management system, warehousing, inventory management, distribution, marketing, and game support functions; supplies player loyalty programs, merchandising services, and interactive marketing campaigns; and sublicenses brands for lottery products and lottery-related promotional products. It also provides software, hardware, and related services for lottery operations; and lottery systems software maintenance and support services. The company's SciPlay segment sells virtual coins, chips, or bingo cards; and third-party branded games and original content through mobile and web platforms. Its Digital segment provides digital gaming and sports wagering solutions and services, including digital RMG and sports wagering solutions, distribution platforms, content, products, and services; software design, development, licensing, maintenance, and support services; Open Platform Systems; and content aggregation platforms. The company was founded in 1984 and is headquartered in Las Vegas, Nevada.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
HADDRILL RICHARD MDirectorJul 24Option Exercise0.0014,1550242,039Jul 24 04:21 PM
Winterscheidt MichaelSVP & Chief Accounting OfficerJul 11Option Exercise0.002,500017,094Jul 13 04:33 PM
Regan Michael JDirectorJun 19Option Exercise0.001,555083,096Jun 19 04:38 PM
COHEN PETER ADirectorJun 19Option Exercise0.001,5550276,894Jun 19 04:37 PM
SCHWARTZ BARRY FDirectorJun 19Option Exercise0.001,5550124,444Jun 19 04:34 PM
TOWNSEND FRANCES FDirectorJun 19Option Exercise0.001,555078,742Jun 19 04:35 PM
PERELMAN RONALD OExecutive ChairmanJun 19Option Exercise0.001,55508,518Jun 19 04:34 PM
SCHWARTZ BARRY FDirectorJun 15Option Exercise0.004,3390122,889Jun 15 04:33 PM
TOWNSEND FRANCES FDirectorJun 15Option Exercise0.004,339077,187Jun 15 04:35 PM
COHEN PETER ADirectorJun 15Option Exercise0.004,3390276,894Jun 15 04:36 PM
Regan Michael JDirectorJun 15Option Exercise0.004,339081,541Jun 15 04:37 PM
PERELMAN RONALD OExecutive ChairmanJun 15Option Exercise0.004,33906,963Jun 15 04:32 PM
PERELMAN RONALD OExecutive ChairmanJun 13Option Exercise0.0069702,624Jun 15 04:32 PM
Regan Michael JDirectorJun 13Option Exercise0.00697077,202Jun 15 04:37 PM
COHEN PETER ADirectorJun 13Option Exercise0.006970272,555Jun 15 04:36 PM
TOWNSEND FRANCES FDirectorJun 13Option Exercise0.00697072,848Jun 15 04:35 PM
SCHWARTZ BARRY FDirectorJun 13Option Exercise0.006970118,550Jun 15 04:33 PM
YOUNGBLOOD DR KNEELANDDirectorJun 12Option Exercise0.001,92701,927Jun 12 04:37 PM
Regan Michael JDirectorJun 12Option Exercise0.001,927076,505Jun 12 04:36 PM
HADDRILL RICHARD MDirectorJun 12Option Exercise0.001,9270227,884Jun 12 04:36 PM
COHEN PETER ADirectorJun 12Option Exercise0.001,9270271,858Jun 12 04:35 PM
TOWNSEND FRANCES FDirectorJun 12Option Exercise0.001,927072,151Jun 12 04:33 PM
SCHWARTZ BARRY FDirectorJun 12Option Exercise0.001,9270117,853Jun 12 04:33 PM
PERELMAN RONALD OExecutive ChairmanJun 12Option Exercise0.001,92701,927Jun 12 04:32 PM
MEISTER PAUL MDirectorJun 10Option Exercise0.0025,622082,740Jun 12 04:41 PM
COTTLE BARRY LPresident and CEOJun 01Option Exercise0.0036,9350154,252Jun 02 04:33 PM
McHugh Patrick JEVP & Grp Chief Exec, LotteryMay 07Option Exercise0.004,868024,356May 08 04:32 PM
Winterscheidt MichaelSVP & Chief Accounting OfficerMar 20Option Exercise0.008,914016,685Mar 23 04:36 PM
Sottile JamesExec VP & Chief Legal OfficerMar 20Option Exercise0.002,76504,715Mar 23 04:35 PM
COTTLE BARRY LPresident and CEOMar 20Option Exercise0.0016,0680117,317Mar 23 04:34 PM
Richardson Stephen ESVP and CCOMar 20Option Exercise0.001,39501,395Mar 23 04:33 PM
McHugh Patrick JEVP & Grp Chief Exec, LotteryMar 20Option Exercise0.0013,083023,424Mar 23 04:31 PM
QUARTIERI MICHAELEVP, CFO, Treas & Corp SecMar 20Option Exercise0.0013,988068,062Mar 23 04:37 PM
COTTLE BARRY LPresident and CEOMar 10Buy10.345,00051,700101,249Mar 10 04:33 PM
Wilson Matthew R.EVP & Grp Chief Exec, GamingMar 01Option Exercise0.0038,556038,556Mar 02 04:42 PM
Kennedy David LDirectorDec 31Option Exercise0.0017,250058,251Dec 31 04:39 PM
Mooberry DerikEVP & Grp Chief Exec, GamingNov 27Option Exercise10.099,921100,15124,337Nov 29 04:23 PM
Mooberry DerikEVP & Grp Chief Exec, GamingNov 27Sale27.159,921269,35514,416Nov 29 04:23 PM
Mooberry DerikEVP & Grp Chief Exec, GamingNov 26Option Exercise14.1832,954467,21347,370Nov 29 04:23 PM
Mooberry DerikEVP & Grp Chief Exec, GamingNov 26Sale28.1932,954928,97314,416Nov 29 04:23 PM
QUARTIERI MICHAELEVP, CFO, Treas & Corp SecNov 11Option Exercise0.006,081056,236Nov 12 07:53 PM
PERELMAN RONALD ODirectorSep 30Buy20.4250,0001,021,00036,793,768Oct 01 07:07 PM
PERELMAN RONALD ODirectorSep 27Buy20.83100,0002,083,00036,743,768Sep 27 06:34 PM
PERELMAN RONALD ODirectorSep 20Buy22.98100,0002,298,00036,643,768Sep 23 05:01 PM
PERELMAN RONALD ODirectorSep 18Buy22.41100,0002,241,00036,543,768Sep 18 08:34 PM
HADDRILL RICHARD MDirectorSep 13Sale23.9445,6811,093,603225,957Sep 17 04:31 PM
Sottile JamesExec VP & Chief Legal OfficerAug 31Option Exercise0.002,19802,658Sep 04 04:32 PM
REV Revlon, Inc. daily Stock Chart
Revlon, Inc.
Index- P/E- EPS (ttm)-5.71 Insider Own0.30% Shs Outstand53.17M Perf Week20.12%
Market Cap438.44M Forward P/E- EPS next Y-1.80 Insider Trans0.00% Shs Float4.08M Perf Month-21.06%
Income-303.30M PEG- EPS next Q-1.04 Inst Own11.70% Short Float54.36% Perf Quarter-31.63%
Sales2.32B P/S0.19 EPS this Y45.60% Inst Trans-6.93% Short Ratio11.77 Perf Half Y-64.65%
Book/sh-27.01 P/B- EPS next Y25.90% ROA-10.00% Target Price7.00 Perf Year-57.27%
Cash/sh1.11 P/C6.98 EPS next 5Y5.00% ROE23.40% 52W Range6.09 - 27.46 Perf YTD-63.77%
Dividend- P/FCF- EPS past 5Y-43.70% ROI3.10% 52W High-71.74% Beta0.86
Dividend %- Quick Ratio0.40 Sales past 5Y4.50% Gross Margin56.40% 52W Low27.42% ATR0.56
Employees7100 Current Ratio0.70 Sales Q/Q-18.10% Oper. Margin-4.40% RSI (14)43.43 Volatility9.88% 7.31%
OptionableYes Debt/Eq- EPS Q/Q-180.80% Profit Margin-12.80% Rel Volume2.28 Prev Close7.08
ShortableYes LT Debt/Eq- EarningsAug 06 BMO Payout- Avg Volume188.45K Price7.76
Recom- SMA20-0.70% SMA50-17.97% SMA200-52.07% Volume417,624 Change9.60%
Sep-13-17Initiated Jefferies Hold $16
Nov-09-09Upgrade BMO Capital Markets Market Perform → Outperform $21
Aug-28-07Initiated BMO Capital Markets Market Perform
Aug-03-07Downgrade Sun Trust Rbsn Humphrey Buy → Neutral
Aug-06-20 07:30AM  
Aug-04-20 07:30AM  
Jul-28-20 08:39AM  
Jul-27-20 06:14PM  
Jul-22-20 01:37PM  
Jul-15-20 08:03AM  
Jul-09-20 10:51AM  
Jun-25-20 01:28PM  
Jun-18-20 08:41AM  
Jun-15-20 09:03PM  
Jun-11-20 09:45AM  
Jun-09-20 10:15AM  
Jun-03-20 03:22AM  
Jun-02-20 10:00AM  
May-21-20 05:00PM  
May-14-20 10:56AM  
May-11-20 07:30AM  
May-10-20 10:50PM  
May-09-20 06:04PM  
May-08-20 04:41PM  
May-04-20 12:40PM  
May-01-20 07:48PM  
Apr-30-20 07:46PM  
Apr-24-20 03:05PM  
Apr-22-20 08:00AM  
Apr-15-20 06:29PM  
Apr-03-20 06:28PM  
Mar-19-20 09:48AM  
Mar-13-20 10:39PM  
Mar-09-20 06:09PM  
Jan-17-20 06:40AM  
Jan-07-20 06:14PM  
Jan-06-20 04:30PM  
Dec-20-19 09:06AM  
Dec-11-19 02:46PM  
Dec-04-19 08:33PM  
Nov-27-19 09:16AM  
Nov-21-19 03:07PM  
Nov-08-19 09:31AM  
Nov-06-19 11:07AM  
Nov-05-19 07:30AM  
Oct-28-19 12:37PM  
Oct-25-19 03:51PM  
Oct-13-19 09:35PM  
Sep-16-19 11:42AM  
Sep-10-19 01:08PM  
Sep-02-19 02:23PM  
Aug-30-19 11:24PM  
Aug-16-19 06:57AM  
Aug-15-19 05:12PM  
Aug-08-19 09:05AM  
Aug-07-19 02:38PM  
Aug-06-19 04:30PM  
Aug-01-19 10:33AM  
Jul-15-19 08:40AM  
Jul-14-19 10:50PM  
Jul-12-19 10:50PM  
Jul-10-19 10:50PM  
Jul-09-19 07:10PM  
Jul-08-19 10:50PM  
Jul-05-19 10:50PM  
Jul-03-19 10:50PM  
Jul-02-19 12:28PM  
Jul-01-19 10:15AM  
Jun-28-19 10:50PM  
Jun-27-19 09:30PM  
Jun-26-19 11:29PM  
Jun-25-19 03:42PM  
Jun-24-19 10:50PM  
Jun-22-19 10:00AM  
Jun-21-19 10:50PM  
Jun-20-19 08:18PM  
Revlon, Inc., through its subsidiaries, develops, manufactures, markets, distributes, and sells beauty and personal care products worldwide. The company's Relvon segment offers color cosmetics and beauty tools under the Revlon brand; and hair color under the Revlon ColorSilk and Revlon Professional brands. Its Elizabeth Arden segment markets, distributes and sells skin care products under the Elizabeth Arden Ceramide, Prevage, Eight Hour, SUPERSTART, Visible Difference, and Skin Illuminating brands; and fragrances under the Elizabeth Arden White Tea, Elizabeth Arden Red Door, Elizabeth Arden 5th Avenue, and Elizabeth Arden Green Tea brands. The company's Portfolio segment offers color cosmetics under the Almay and SinfulColors brands; men's grooming products under the American Crew brand; nail polishes, gel nail color, and nail enhancements under the CND brand; nail care products under the Cutex brand; anti-perspirant deodorants under the Mitchum brand; hair care products under the Creme of Nature; and hair color line under the Llongueras brand. Its Fragrances segment develops, markets, and distributes owned and licensed fragrances, as well as distributes prestige fragrance brands owned by third parties. This segment offers its products under the Juicy Couture, John Varvatos, AllSaints, Britney Spears, Elizabeth Taylor, Christina Aguilera, Jennifer Aniston, Mariah Carey, Curve, Giorgio Beverly Hills, Ed Hardy, Charlie, Lucky Brand, APSA, Alfred Sung, Halston, Geoffrey Beene, and White Diamonds brands. The company sells its products through sales force, sales representatives, and independent distributors, as well as licenses its Revlon, The Elizabeth Arden, and Red Door trademarks to the manufacturers of complementary beauty-related products and accessories. Revlon, Inc. was founded in 1932 and is based in New York, New York.